We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
Cell therapies have grown to become a prevailing field dominating new medical breakthroughs with the promise of treatments and cures for multiple diseases. The biopharma hubs of Philadelphia and Maryland have emerged as important drivers of this new wave of medicine, build on the foundation of renowned research institutes, universities, and a number of successful cell therapy companies who have paved the way forward in this field.
The next major wave of treatment options for multiple diseases is cell therapies, and Gaithersburg-based MaxCyte is one of the companies driving this revolution.
MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.
MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial offering price of US$13.00 per share (the “Offering”).
he company signed a 13-year, 67,000-square-foot lease at 9713 Key West Avenue, a five-story, 120,000-square-foot office building, with landlord Beckham Gumbin Ventures.
Celularity and Gaithersburg’s MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates
Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic platform license.
At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy ProgramsPublished on :
Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.